361 Capital’s NuVasive, Inc. NUVA Stock Holding History

361 Capital’s Portfolio NUVA Stock Details NUVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$690K	Sell	12,396 -1,924	-13%	-$111K	0.32%	162
2020 Q1	$725K	Sell	14,320 -14,057	-50%	-$943K	0.33%	137
2019 Q4	$2.19M	Buy	+28,377	New	+$2M	0.61%	9

Other funds holding NUVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

361 Capital's NUVA Position: Q2 2020 in Review

361 Capital reduced its NuVasive, Inc. (NUVA) stake by 13% in Q2 2020, selling an estimated $111K and leaving 12,396 shares worth $690K. The position accounts for 0.32% of the portfolio, ranked #162.

361 Capital first reported a position in NUVA in Q4 2019 and has held it in 3 quarters since. The position peaked at $2.19M in Q4 2019. 290 funds tracked by Wall St. Rank hold NUVA as of Q2 2020.

361 Capital held 12,396 shares of NuVasive, Inc. worth $690K as of Q2 2020.
361 Capital sold 1,924 NuVasive, Inc. shares in Q2 2020, an estimated $111K.
NuVasive, Inc. made up 0.32% of 361 Capital's portfolio in Q2 2020, its #162 holding.
361 Capital first reported a position in NuVasive, Inc. in Q4 2019 and has held it in 3 quarters since.
361 Capital's NuVasive, Inc. position peaked at $2.19M in Q4 2019.
290 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.